Equities researchers at Truist Financial initiated coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat.com reports. The brokerage set a "buy" rating and a $21.00 price target on the stock. Truist Financial's target price would suggest a potential upside of 73.84% from the stock's current price.
A number of other research firms have also weighed in on YMAB. BMO Capital Markets boosted their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an "outperform" rating in a report on Monday, March 4th. HC Wainwright increased their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Monday, May 13th. Finally, Canaccord Genuity Group raised their target price on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a research report on Monday, March 4th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $17.86.
View Our Latest Analysis on YMAB
Y-mAbs Therapeutics Stock Performance
Shares of Y-mAbs Therapeutics stock traded down $0.25 during midday trading on Friday, hitting $12.08. 1,349,380 shares of the company traded hands, compared to its average volume of 390,527. The firm's fifty day moving average price is $13.07 and its 200-day moving average price is $12.78. The stock has a market cap of $530.07 million, a price-to-earnings ratio of -24.65 and a beta of 0.69. Y-mAbs Therapeutics has a 12 month low of $4.60 and a 12 month high of $20.90.
Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03). The company had revenue of $19.93 million for the quarter, compared to the consensus estimate of $22.06 million. Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. Equities research analysts forecast that Y-mAbs Therapeutics will post -0.45 earnings per share for the current year.
Insider Buying and Selling
In other news, insider Thomas Gad sold 25,000 shares of Y-mAbs Therapeutics stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total value of $300,000.00. Following the completion of the transaction, the insider now directly owns 240,032 shares of the company's stock, valued at approximately $2,880,384. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CFO Bo Kruse sold 31,371 shares of the stock in a transaction on Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the transaction, the chief financial officer now directly owns 210,877 shares of the company's stock, valued at $2,545,285.39. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas Gad sold 25,000 shares of Y-mAbs Therapeutics stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $12.00, for a total transaction of $300,000.00. Following the completion of the sale, the insider now directly owns 240,032 shares of the company's stock, valued at $2,880,384. The disclosure for this sale can be found here. Insiders sold 99,444 shares of company stock valued at $1,203,925 over the last quarter. Insiders own 21.50% of the company's stock.
Institutional Trading of Y-mAbs Therapeutics
Several large investors have recently made changes to their positions in YMAB. Trexquant Investment LP increased its stake in Y-mAbs Therapeutics by 417.5% during the 3rd quarter. Trexquant Investment LP now owns 76,585 shares of the company's stock valued at $417,000 after purchasing an additional 61,785 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Y-mAbs Therapeutics by 208.3% during the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company's stock worth $748,000 after acquiring an additional 92,765 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of Y-mAbs Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 28,095 shares of the company's stock worth $192,000 after acquiring an additional 7,124 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Y-mAbs Therapeutics by 17.5% in the 4th quarter. SG Americas Securities LLC now owns 21,559 shares of the company's stock worth $147,000 after acquiring an additional 3,210 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Y-mAbs Therapeutics in the 4th quarter valued at about $34,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.
Y-mAbs Therapeutics Company Profile
(Get Free Report)
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Further Reading
- Five stocks we like better than Y-mAbs Therapeutics
- What Are Dividend Champions? How to Invest in the Champions
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What Are the FAANG Stocks and Are They Good Investments?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What Makes a Stock a Good Dividend Stock?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
→ The END of Joe Biden (From Banyan Hill Publishing) (Ad)
Should you invest $1,000 in Y-mAbs Therapeutics right now?
Before you consider Y-mAbs Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Y-mAbs Therapeutics wasn't on the list.
While Y-mAbs Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
10 "Recession Proof" Stocks That Will Thrive in Any Market
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
